Afatinib

Results: 28



#Item
11Notice : Information du patient GIOTRIF® 40 mg comprimés pelliculés afatinib Ce médicament fait l’objet d’une surveillance supplémentaire qui permettra l’identification rapide de nouvelles informations relativ

Notice : Information du patient GIOTRIF® 40 mg comprimés pelliculés afatinib Ce médicament fait l’objet d’une surveillance supplémentaire qui permettra l’identification rapide de nouvelles informations relativ

Add to Reading List

Source URL: www.boehringer-ingelheim.be

Language: French - Date: 2016-01-16 03:52:56
    12Bijsluiter: Informatie voor de patiënt GIOTRIF® 40 mg filmomhulde tabletten afatinib Dit geneesmiddel is onderworpen aan aanvullende monitoring. Daardoor kan snel nieuwe veiligheidsinformatie worden vastgesteld. U kunt

    Bijsluiter: Informatie voor de patiënt GIOTRIF® 40 mg filmomhulde tabletten afatinib Dit geneesmiddel is onderworpen aan aanvullende monitoring. Daardoor kan snel nieuwe veiligheidsinformatie worden vastgesteld. U kunt

    Add to Reading List

    Source URL: www.boehringer-ingelheim.be

    Language: Dutch - Date: 2016-01-23 14:21:35
      13Quinazolines / Tyrosine kinase receptors / Organofluorides / Amines / Organochlorides / Gefitinib / Erlotinib / Epidermal growth factor receptor / Afatinib / Chemistry / Organic chemistry / Medicine

      1293 Consultation Decision Analytic Protocol (DAP) to guide the assessment of Epidermal Growth Factor Receptor (EGFR) gene mutation testing for eligibility for afatinib treatment in patients with stage IIIB or stage IV

      Add to Reading List

      Source URL: www.msac.gov.au

      Language: English - Date: 2014-11-06 23:49:25
      14Quinazolines / Organofluorides / Amines / Organochlorides / Lung cancer / Gefitinib / Erlotinib / Epidermal growth factor receptor / Afatinib / Chemistry / Organic chemistry / Medicine

      1293 Final Decision Analytic Protocol (DAP) to guide the assessment of Epidermal Growth Factor Receptor (EGFR) gene mutation testing for eligibility for afatinib treatment in patients with stage IIIB or stage IV non-sma

      Add to Reading List

      Source URL: www.msac.gov.au

      Language: English - Date: 2014-11-06 23:49:26
      15Quinazolines / Organofluorides / Amines / Organochlorides / Lung cancer / Gefitinib / Erlotinib / Epidermal growth factor receptor / Non-small-cell lung carcinoma / Chemistry / Organic chemistry / Medicine

      Public Summary Document Application No. 1293 – Epidermal Growth Factor Receptor (EGFR) testing to determine eligibility for afatinib treatment in patients with locally advanced or metastatic non-small-cell lung cancer

      Add to Reading List

      Source URL: www.msac.gov.au

      Language: English - Date: 2014-11-06 23:49:26
      16Public Summary Document Application No. 1293 – Epidermal Growth Factor Receptor (EGFR) testing to determine eligibility for afatinib treatment in patients with locally advanced or metastatic non-small-cell lung cancer

      Public Summary Document Application No. 1293 – Epidermal Growth Factor Receptor (EGFR) testing to determine eligibility for afatinib treatment in patients with locally advanced or metastatic non-small-cell lung cancer

      Add to Reading List

      Source URL: www.msac.gov.au

      Language: English - Date: 2014-11-06 23:49:25
      17Microsoft Word[removed]EGFR-Consultation DAP .doc

      Microsoft Word[removed]EGFR-Consultation DAP .doc

      Add to Reading List

      Source URL: www.msac.gov.au

      Language: English - Date: 2014-11-06 23:49:26
      18Microsoft Word[removed]EGFR-FinalDAP.doc

      Microsoft Word[removed]EGFR-FinalDAP.doc

      Add to Reading List

      Source URL: www.msac.gov.au

      Language: English - Date: 2014-11-06 23:49:25
      19NATIONAL CANCER DRUG FUND PRIORITISATION SCORES Drug Indication  AFATINIB

      NATIONAL CANCER DRUG FUND PRIORITISATION SCORES Drug Indication AFATINIB

      Add to Reading List

      Source URL: www.england.nhs.uk

      Language: English - Date: 2014-02-03 09:11:16
      20Press Release For US Media Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy 

      Press Release For US Media Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy 

      Add to Reading List

      Source URL: www.curevac.com

      Language: English - Date: 2014-09-18 07:07:16